Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625136 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL29049316 | 0.80 | SMN1; SMN2 (0.31) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3852439 | 0.80 | ALDH1A1 (0.32) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL476049 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL8764997 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL12567309 | 0.78 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL11158482 | 0.78 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL10965455 | 0.78 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL10873860 | 0.78 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL1985795 | 0.78 | CA1 (0.35) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | US | claimed |
| CN-106999604-B | Methods for formulating antibody drug conjugate compositions | 伊缪诺金公司 | 2021-08-03 | — | — | CN | claimed |
| EP-3555137-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Development Center for Biotechnology (TW) | 2019-10-23 | — | — | EP | claimed |
| WO-2018112027-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2018-06-21 | — | — | WO | claimed |
| EP-3188761-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | ImmunoGen, Inc. (US) | 2017-07-12 | — | — | EP | claimed |
| US-20160115238-A1 | CD20 Antibodies and Uses Thereof | IMMUNOGEN, INC. | 2016-04-28 | — | — | US | claimed |
| US-20160108126-A1 | CD20 Antibodies and Uses Thereof | IMMUNOGEN, INC. | 2016-04-21 | — | — | US | claimed |
| WO-2016036861-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | claimed |
| US-20160058884-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-03 | — | — | US | claimed |
| US-9173961-B2 | CD20 antibodies and uses thereof | IMMUNOGEN, INC. (US) | 2015-11-03 | — | — | US | claimed |
| US-9175086-B2 | CD20 antibodies and uses thereof | IMMUNOGEN, INC. (US) | 2015-11-03 | — | — | US | claimed |
| CN-105001334-A | CD20 antibodies and uses thereof | IMMUNOGEN INC | 2015-10-28 | — | — | CN | claimed |
| CN-102933231-B | CD20 antibodies and uses thereof | IMMUNOGEN INC. (US) | 2015-07-29 | — | — | CN | claimed |
| CN-102933231-A | Cd20 antibodies and uses thereof | IMMUNOGEN INC | 2013-02-13 | — | — | CN | claimed |
| EP-2533810-A1 | CD20 ANTIBODIES AND USES THEREOF | ImmunoGen, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| WO-2011100403-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC (US) | 2011-08-18 | — | — | WO | claimed |
| WO-2011100398-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-08-18 | — | — | WO | claimed |
| US-20110195022-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | claimed |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | claimed |
| CN-122075735-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4724492-A1 | NOVEL ANTIBODIES TARGETING CD3 AND ANOTHER TARGET AND USES THEREOF | Antengene Biologics Limited (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-3349796-B1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | IMMUNOGEN INC (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2026041038-A1 | NOVEL ANTI-CDH6 ANTIBODIES AND USES THEREOF | ANTENGENE (HANGZHOU) BIOLOGICS CO., LTD. (CN) | 2026-02-26 | — | — | WO | disclosed |
| US-12559566-B2 | CD37-binding molecules immunoconjugates thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2026-02-24 | — | — | US | disclosed |
| US-20250368734-A1 | NOVEL ANTI-GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | ANTENGENE BIOLOGICS LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250361295-A1 | NOVEL ANTI-LILRB4 ANTIBODIES AND USES THEREOF | ANTENGENE BIOLOGICS LTD (CN) | 2025-11-27 | — | — | US | disclosed |
| US-20250345452-A1 | METHODS FOR THE TREATMENT OF PATIENTS WITH FOLATE RECEPTOR ALPHA-EXPRESSING CANCERS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20250262217-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | IMMUNOGEN, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250228960-A1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250223358-A1 | NOVEL ANTI-CD3 ANTIBODIES AND USES THEREOF | ANTENGENE BIOLOGICS LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4577573-A1 | NOVEL ANTI-LILRB2 ANTIBODIES AND USES THEREOF | Antengene Biologics Limited (CN) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025126157-A1 | ANTI-IL-1RAP BINDING DOMAINS AND ANTIBODY-DRUG CONJUGATES THEREOF | ADVESYA (FR) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025119253-A1 | NOVEL ANTIBODIES THAT BIND TO CD3 AND LILRB4, AND USES THEREOF | ANTENGENE (HANGZHOU) BIOLOGICS CO., LTD. (CN) | 2025-06-12 | — | — | WO | disclosed |
| US-20250127793-A1 | CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS | REVOPSIS HOLDINGS, LLC | 2025-04-24 | — | — | US | disclosed |
| EP-4532561-A1 | NOVEL ANTI-GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | Antengene Biologics Limited (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119768432-A | Novel anti-LILRB 2 antibodies and uses thereof | 德琪(杭州)生物有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-12239732-B2 | Anti-CD37 immunoconjugate and anti-CD20 antibody combinations | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2025-03-04 | — | — | US | disclosed |
| WO-2025027529-A1 | ANTI-IL-1RAP ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | ADVESYA (FR) | 2025-02-06 | — | — | WO | disclosed |
| CN-119343376-A | Novel anti-LILRB 4 antibodies and uses thereof | 德琪(杭州)生物有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4490194-A1 | NOVEL ANTI-CD3 ANTIBODIES AND USES THEREOF | Antengene Biologics Limited (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119278217-A | Novel anti-GPRC 5D antibodies, bispecific antigen binding molecules binding to GPRC5D and CD3 and uses thereof | 德琪(杭州)生物有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119185571-A | Anti-FOLR 1 immunoconjugate dosing regimen | 伊缪诺金公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024251242-A1 | NOVEL ANTIBODIES TARGETING CD3 AND ANOTHER TARGET AND USES THEREOF | ANTENGENE (HANGZHOU) BIOLOGICS CO., LTD. (CN) | 2024-12-12 | — | — | WO | disclosed |
| CN-118974087-A | Novel anti-CD 3 antibodies and uses thereof | 德琪(杭州)生物有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240376169-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY | 2024-11-14 | — | — | US | disclosed |
| US-20240368270-A1 | ANTI-FOLR1 IMMUNOCONJUGATE REGIMENS | IMMUNOGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4424323-A2 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | ImmunoGen, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240270839-A1 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | ELPISCIENCE (SUZHOU) BIOPHARMA, LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4382535-A2 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Washington University (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-3653228-B1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240132585-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-3875152-B1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY ST LOUIS (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11938193-B2 | Compositions comprising chemerin and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240092854-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY | 2024-03-21 | — | — | US | disclosed |
| EP-4335851-A2 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | ImmunoGen, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240075155-A1 | COMPOSITIONS COMPRISING CHEMERIN AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2024-03-07 | — | — | US | disclosed |
| WO-2024041315-A1 | NOVEL ANTI-LILRB2 ANTIBODIES AND USES THEREOF | ANTENGENE (HANGZHOU) BIOLOGICS CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| US-11897929-B2 | Compositions and methods for targeted cytokine delivery | WASHINGTON UNIVERSITY (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4309671-A2 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | ImmunoGen, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023236891-A1 | NOVEL ANTI-LILRB4 ANTIBODIES AND USES THEREOF | ANTENGENE (HANGZHOU) BIOLOGICS CO., LTD. (CN) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023227062-A1 | NOVEL ANTI-GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | ANTENGENE (HANGZHOU) BIOLOGICS CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | US | disclosed |
| EP-3380525-B1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN INC (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116120461-B | Novel anti-drug antibodies and uses thereof | 德琪(杭州)生物有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230287137-A1 | CD37-BINDING MOLECULES IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023169419-A1 | NOVEL ANTI-CD3 ANTIBODIES AND USES THEREOF | ANTENGENE (HANGZHOU) BIOLOGICS CO., LTD. (CN) | 2023-09-14 | — | — | WO | disclosed |
| EP-3636279-B1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4217396-A1 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | Elpiscience (Suzhou) Biopharma, Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-11713342-B2 | Compositions and methods for targeted cytokine delivery | WASHINGTON UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| CN-109071679-B | Compositions and methods for targeted cytokine delivery | 华盛顿大学 | 2023-07-28 | — | — | CN | disclosed |
| CN-116472350-A | Novel anti-CLDN 18 antibodies | 科望(苏州)生物医药科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116440279-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | 伊缪诺金公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230190638-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | IMMUNOGEN, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-116120461-A | Novel anti-drug antibodies and uses thereof | 德琪(杭州)生物有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-108601828-B | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | 伊缪诺金公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4125953-A2 | NOVEL ANUCLEATED CELLS AND USES THEREOF | Platelet Biogenesis, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220378694-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | IMMUNOGEN, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| US-11466095-B2 | CD37-binding molecules and immunoconjugates thereof | DEBIOPHARM INTERNATIONAL S.A. | 2022-10-11 | — | — | US | disclosed |
| US-20220267371-A1 | METHODS FOR ANTIBODY DRUG CONJUGATION, PURIFICATION, AND FORMULATION | IMMUNOGEN, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20220257765-A1 | TARGET-SPECIFIC CONJUGATE AND USE THEREFOR | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2022-08-18 | — | — | US | disclosed |
| US-11395796-B2 | Anti-CD37 immunoconjugate and anti-CD20 antibody combinations | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2022-07-26 | — | — | US | disclosed |
| US-20220168326-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220143208-A1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| CN-114441757-A | Methods for increasing the efficacy of FOLR1 cancer treatment | 伊缪诺金公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022063272-A1 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | ELPISCIENCE (SUZHOU) BIOPHARMA, LTD. (CN) | 2022-03-31 | — | — | WO | disclosed |
| US-11278628-B2 | Pharmaceutical formulations and methods of use thereof | IMMUNOGEN, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11274121-B2 | Methods for antibody drug conjugation, purification, and formulation | IMMUNOGEN, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-113842468-A | Methods for formulating antibody drug conjugate compositions | 伊缪诺金公司 | 2021-12-28 | — | — | CN | disclosed |
| US-11135305-B2 | Methods for increasing efficacy of FOLR1 cancer therapy | IMMUNOGEN, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| WO-2021195496-A2 | NOVEL ANUCLEATED CELLS AND USES THEREOF | PLATELET BIOGENESIS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210284706-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-16 | — | — | US | disclosed |
| EP-3875152-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Washington University (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-106999604-B | Methods for formulating antibody drug conjugate compositions | 伊缪诺金公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11053293-B2 | Compositions and methods for targeted cytokine delivery | WASHINGTON UNIVERSITY | 2021-07-06 | — | — | US | disclosed |
| US-11033564-B2 | Therapeutic combinations comprising anti-FOLR1 immunoconjugates | IMMUNOGEN, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210155688-A1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN, INC. | 2021-05-27 | — | — | US | disclosed |
| EP-3233192-B1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | UNIV WASHINGTON (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-2804631-B1 | SURROBODY CONJUGATES | I2 PHARMACEUTICALS INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20210032327-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| US-20210032306-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-04 | — | — | US | disclosed |
| EP-3760643-A1 | IMMUNOCONJUGATES COMPRISING A FOLATE RECEPTOR 1 ANTIBODY | ImmunoGen, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200397806-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | IMMUNOGEN SWITZERLAND GMBH (CH) | 2020-12-24 | — | — | US | disclosed |
| EP-3737421-A1 | METHODS FOR ANTIBODY DRUG CONJUGATION, PURIFICATION, AND FORMULATION | Immunogen, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200330615-A1 | NONINVASIVE IMAGING OF FOCAL ATHEROSCLEROTIC LESIONS USING FLUORESCENCE MOLECULAR TOMOGRAPHY | WASHINGTON UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| US-10793613-B2 | Compositions and methods for targeted cytokine delivery | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-06 | — | — | US | disclosed |
| US-20200270361-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. | 2020-08-27 | — | — | US | disclosed |
| CN-111587125-A | Methods for antibody drug conjugation, purification and formulation | 伊缪诺金公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10752683-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200222552-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN, INC. | 2020-07-16 | — | — | US | disclosed |
| CN-106046159-B | CD37 binding molecules and immunoconjugates thereof | 德彪发姆国际有限公司 | 2020-06-16 | — | — | CN | disclosed |
| EP-3196212-B1 | IMMUNOCONJUGATES COMPRISING A FOLATE RECEPTOR 1 ANTIBODY | IMMUNOGEN INC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3653228-A1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | ImmunoGen, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3636279-A1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | ImmunoGen, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10603388-B2 | Methods for formulating antibody drug conjugate compositions | IMMUNOGEN, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3620467-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Debiopharm International SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20200046737-A1 | METHODS FOR TREATING CANCER, AND COMPOSITIONS THEREFOR | NOTABLE LABS INC (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200046634-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | IMMUNOGEN, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2020033851-A1 | COMPOSITIONS COMPRISING PRIMING AGENTS AND THEIR USE IN THE TREATMENT OF CANCER | Notable Labs, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-10556958-B2 | CD37-binding molecules and immunoconjugates thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2020-02-11 | — | — | US | disclosed |
| US-20190345248-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3555137-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Development Center for Biotechnology (TW) | 2019-10-23 | — | — | EP | disclosed |
| EP-3055332-B1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190270769-A1 | METHODS FOR ANTIBODY DRUG CONJUGATION, PURIFICATION, AND FORMULATION | IMMUNOGEN, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3318273-B1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190218303-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | IMMUNOGEN, INC. | 2019-07-18 | — | — | US | disclosed |
| EP-2544719-B1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | DEBIOPHARM INT SA (CH) | 2019-07-03 | — | — | EP | disclosed |
| US-20190183788-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | IMMUNOGEN, INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190167704-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | IMMUNOGEN SWITZERLAND GMBH (CH) | 2019-06-06 | — | — | US | disclosed |
| US-10301385-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190127482-A1 | CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS | REVOPSIS HOLDINGS, LLC | 2019-05-02 | — | — | US | disclosed |
| US-20190119345-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY | 2019-04-25 | — | — | US | disclosed |
| US-20190092831-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| US-10202460-B2 | CD37-binding molecules and immunoconjugates thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20190008982-A1 | COMPOSITIONS COMPRISING CHEMERIN AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2019-01-10 | — | — | US | disclosed |
| US-10172875-B2 | Therapeutic combinations comprising anti-FOLR1 immunoconjugates | IMMUNOGEN, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3411414-A2 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Washington University (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-2754693-B1 | EMBEDDING RESIN COMPOSITION FOR ELECTRON MICROSCOPE, AND METHOD FOR OBSERVING SAMPLE ON ELECTRON MICROSCOPE USING SAID COMPOSITION | UNIV KURUME (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-3380525-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | Immunogen, Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-3349796-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | ImmunoGen, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180200383-A1 | Methods for Increasing Efficacy of FOLR1 Cancer Therapy | IMMUNOGEN, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| CN-108290895-A | Process for preparing cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2018-07-17 | — | — | CN | disclosed |
| WO-2018112027-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2018-06-21 | — | — | WO | disclosed |
| EP-3318273-A1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | ImmunoGen, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3311846-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | ImmunoGen, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3302561-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | Debiopharm International SA (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-9870894-B2 | Embedding resin composition for electron microscopey and method for observing sample with electron microscope using the same | KURUME UNIVERSITY (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20170348428-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348427-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170327575-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| EP-3233192-A2 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Washington University (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170239367-A1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN INC (US) | 2017-08-24 | — | — | US | disclosed |
| WO-2017136818-A2 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY (US) | 2017-08-10 | — | — | WO | disclosed |
| EP-3196212-A1 | IMMUNOCONJUGATES COMPRISING A FOLATE RECEPTOR 1 ANTIBODY | Immunogen, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017120589-A1 | COMPOSITIONS COMPRISING CHEMERIN AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-3188761-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | ImmunoGen, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170189548-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN, INC. | 2017-07-06 | — | — | US | disclosed |
| US-9670280-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670279-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670278-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017091745-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-9657100-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170095571-A1 | Therapeutic Combinations Comprising Anti-FOLR1 Immunoconjugates | IMMUNOGEN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095577-A1 | NONINVASIVE IMAGING OF FOCAL ATHEROSCLEROTIC LESIONS USING FLUORESCENCE MOLECULAR TOMOGRAPHY | WASHINGTON UNIVERSITY | 2017-04-06 | — | — | US | disclosed |
| WO-2017049149-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | IMMUNOGEN, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-9598490-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3134126-A1 | PHARMACEUTICAL FORMULATION OF AN ANTI-GUANYLYL CYCLASE C ANTIBODY CONJUGATE COMPRISING HISTIDINE OR A SALT THEREOF AND POLYSORBATE 20 | Millennium Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170000900-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2017-01-05 | — | — | US | disclosed |
| WO-2016200676-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | IMMUNOGEN, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160354486-A1 | BINDING MOLECULE CONJUGATES | SEA LANE BIOTECHNOLOGIES, LLC. | 2016-12-08 | — | — | US | disclosed |
| EP-2538976-B1 | IMMUNOCONJUGATES AGAINST FOLATE RECEPTOR 1 AND USES THEREOF | IMMUNOGEN INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160340438-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160326258-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | IMMUNOGEN, INC. | 2016-11-10 | — | — | US | disclosed |
| EP-2533810-B1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9447189-B2 | CD37-binding molecules and immunoconjugates thereof | IMMUNOGEN, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| CN-103045268-B | Crystal aligning agent, liquid crystal orienting film and liquid crystal display cells | JSR株式会社 | 2016-09-14 | — | — | CN | disclosed |
| EP-3055332-A2 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | Immunogen, Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-3041952-A1 | COMPOSITIONS FOR RNA-CHROMATIN INTERACTION ANALYSIS AND USES THEREOF | The Jackson Laboratory (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016100375-A2 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9346887-B2 | CD37-binding molecules and immunoconjugates thereof | IMMUNOGEN, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160115238-A1 | CD20 Antibodies and Uses Thereof | IMMUNOGEN, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160108126-A1 | CD20 Antibodies and Uses Thereof | IMMUNOGEN, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160096887-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096888-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160083471-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2997044-A2 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | ImmunoGen, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20160075781-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| WO-2016036861-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160060345-A1 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof | IMMUNOGEN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058884-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060339-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160017053-A1 | Non-Antagonistic EGFR-Binding Molecules and Immunoconjugates Thereof | IMMUNOGEN, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9238690-B2 | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof | IMMUNOGEN, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9233171-B2 | Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate | IMMUNOGEN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150343077-A1 | Anti-CD37 Immunoconjugate Dosing Regimens | IMMUNOGEN, INC. | 2015-12-03 | — | — | US | disclosed |
| WO-2015175533-A2 | ANTI-CD37 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-9175086-B2 | CD20 antibodies and uses thereof | IMMUNOGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173961-B2 | CD20 antibodies and uses thereof | IMMUNOGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015164581-A1 | PHARMACEUTICAL FORMULATION OF AN ANTI-GUANYLYL CYCLASE C ANTIBODY CONJUGATE COMPRISING HISTIDINE OR A SALT THEREOF AND POLYSORBATE 20 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| CN-105001334-A | CD20 antibodies and uses thereof | IMMUNOGEN INC | 2015-10-28 | — | — | CN | disclosed |
| US-20150297744-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | IMMUNOGEN, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2015149018-A1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-9133275-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9125896-B2 | EGFR-binding molecules and immunoconjugates thereof | IMMUNOGEN, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| CN-102933231-B | CD20 antibodies and uses thereof | IMMUNOGEN INC. (US) | 2015-07-29 | — | — | CN | disclosed |
| US-20150175794-A1 | ALKALI-SOLUBLE RESIN COMPONENT AND PHOTOSENSITIVE RESIN COMPOSITION COMPRISING THE SAME | CHI MEI CORPORATION (TW) | 2015-06-25 | — | — | US | disclosed |
| EP-2882449-A2 | SUPERKINES AND SYNTHEKINES: REPURPOSED CYTOKINES WITH NEW AND ENHANCED SIGNALING ACTIVITIES | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2015-06-17 | — | — | EP | disclosed |
| US-20150132323-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | IMMUNOGEN, INC. | 2015-05-14 | — | — | US | disclosed |
| WO-2015054400-A2 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150093397-A1 | Methods for Increasing Efficacy of CD37-Based Therapy | IMMUNOGEN, INC. | 2015-04-02 | — | — | US | disclosed |
| EP-1819359-B1 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS OF THEIR PRODUCTION AND THEIR USE | JANSSEN BIOTECH INC (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2015035108-A1 | COMPOSITIONS FOR RNA-CHROMATIN INTERACTION ANALYSIS AND USES THEREOF | THE JACKSON LABORATORY (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2831585-A2 | METHODS FOR INCREASING EFFICACY OF CD37-BASED THERAPY | ImmunoGen, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| US-20150011736-A1 | BINDING MOLECULE CONJUGATES | ALTUS BIOPHARMA INC. | 2015-01-08 | — | — | US | disclosed |
| US-20140363451-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | IMMUNOGEN, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140363453-A1 | Methods for Increasing Efficacy of FOLR1 Cancer Therapy | IMMUNOGEN, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| EP-2804631-A1 | SURROBODY COJUGATES | Sea Lane Biotechnologies,llc. (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014186403-A2 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN INC. (US) | 2014-11-20 | — | — | WO | disclosed |
| EP-2794010-A1 | METHOD OF TREATMENT OF TUMORS THAT ARE RESISTANT TO EGFR THERAPIES BY EGFR ANTIBODY CYTOTOXIC AGENT CONJUGATE | ImmunoGen, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8834920-B2 | Liposome composition for targeting egfr receptor | ALZA CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140212913-A1 | EMBEDDING RESIN COMPOSITION FOR ELECTRON MICROSCOPE, AND METHOD FOR OBSERVING SAMPLE ON ELECTRON MICROSCOPE USING SAID COMPOSITION | KURUME UNIVERSITY (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8790649-B2 | EGFR-binding molecules and immunoconjugates thereof | IMMUNOGEN, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8765917-B2 | CD37-binding molecules and immunoconjugates thereof | IMMUNOGEN, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2014074186-A2 | SUPERKINES AND SYNTHEKINES: REPURPOSED CYTOKINES WITH NEW AND ENHANCED SIGNALING ACTIVITIES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-8709432-B2 | Methods for increasing efficacy of FOLR1 cancer therapy | IMMUNOGEN, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140099308-A1 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| EP-1229934-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | IMMUNOGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2694106-A2 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | Immunogen, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694105-A2 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140023662-A1 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8603483-B2 | Anti-integrin immunoconjugates, methods and uses | JANSSEN BIOTECH, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130295119-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130295104-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8557966-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2013149171-A2 | METHODS FOR INCREASING EFFICACY OF CD37-BASED THERAPY | IMMUNOGEN, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8536113-B2 | EGFR binding peptides and uses thereof | JANSSEN BIOTECH, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2632490-A2 | NOVEL EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632947-A2 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2013109994-A1 | SURROBODY COJUGATES | SEA LANE BIOTECHNOLOGIES, LLC (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20130156796-A1 | Method of Treatment of Tumors That Are Resistant to EGFR Therapies by EGFR Antibody Cytotoxic Agent Conjugate | IMMUNOGEN, INC. | 2013-06-20 | — | — | US | disclosed |
| WO-2013078271-A1 | METHOD OF TREATMENT OF TUMORS THAT ARE RESISTANT TO EGFR THERAPIES BY EGFR ANTIBODY CYTOTOXIC AGENT CONJUGATE | IMMUNOGEN, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| CN-102933231-A | Cd20 antibodies and uses thereof | IMMUNOGEN INC | 2013-02-13 | — | — | CN | disclosed |
| EP-2544719-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | Immunogen, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2538976-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | Immunogen, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-RE43899-E1 | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | IMMUNOGEN INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2533810-A1 | CD20 ANTIBODIES AND USES THEREOF | ImmunoGen, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120282175-A1 | Methods for Increasing Efficacy of FOLR1 Cancer Therapy | IMMUNOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012149412-A2 | ANTI-ENDOGLIN (CD105) ANTIBODIES, IMMUNOCONJUGATES, AND USES THEREOF | IMMUNOGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120276119-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| WO-2012135675-A2 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135740-A2 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8278415-B2 | Dimeric high affinity EGFR constructs and uses thereof | CENTOCOR, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2490720-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120213844-A1 | LIPOSOME COMPOSITION FOR TARGETING EGFR RECEPTOR | HUANG KEN SHI KUN (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120156217-A1 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof | IMMUNOGEN, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012058592-A2 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058588-A2 | NOVEL EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012019024-A2 | HER3-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120009181-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN SWITZERLAND GMBH (CH) | 2012-01-12 | — | — | US | disclosed |
| WO-2011162933-A1 | ANTI-INTEGRIN IMMUNOCONJUGATE DOSING REGIMENS | IMMUNOGEN, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110256153-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2011112978-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011106528-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011100403-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100398-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110195022-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | disclosed |
| WO-2011050242-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| EP-2289549-A2 | Immunoconjugates for treating cancer | Immunogen, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2266607-A2 | Immunoconjugates for treating cancer | Immunogen, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100151003-A1 | EGFR BINDING PEPTIDES AND USES THEREOF | JANSSEN BIOTECH, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100098681-A1 | DIMERIC HIGH AFFINITY EGFR CONSTRUCTS AND USES THEREOF | WANG BRYAN | 2010-04-22 | — | — | US | disclosed |
| US-7601354-B2 | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | IMMUNOGEN INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2008079982-A2 | LIPOSOME COMPOSITION FOR TARGETING EGFR RECEPTOR | CENTOCOR, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079976-A2 | DIMERIC HIGH AFFINITY EGFR CONSTRUCTS AND USES THEREOF | CENTOCOR, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079973-A2 | EGFR BINDING PEPTIDES AND USES THEREOF | CENTOCOR, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-7361347-B2 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-22 | — | — | US | disclosed |
| US-7303749-B1 | Immunoconjugate of a maytansine linked to a monoclonal antibody that binds to an antigen expressed by a cancer cell, and a taxane, an epothilone, a platinum compound, an epipodophyllotoxin, and/or a camptothecin | IMMUNOGEN INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1819359-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | Centocor, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060233811-A1 | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | IMMUNOGEN INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2006062779-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | CENTOCOR, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | JANSSEN BIOTECH, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | ADOLF GUENTHER | 2005-12-08 | — | — | US | disclosed |
| US-20050244413-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | ADOLF GUENTHER | 2005-11-03 | — | — | US | disclosed |
| EP-1392360-A4 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | CORNELL RES FOUNDATION INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1229934-A4 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | IMMUNOGEN INC (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040126379-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| US-20040120949-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20040110933-A1 | Comprises cartilage link transmembrane protein for diagnosis and treatment of inflammatory, arthritic, restenotic and cell proliferative disorders | DYAX CORPORATION | 2004-06-10 | — | — | US | disclosed |
| WO-2004041307-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES AND RADIOTHERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
| EP-1417974-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy | Boehringer Ingelheim International GmbH (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004024750-A2 | CD44-BINDING LIGANDS | DYAX CORPORATION (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1395290-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1392360-A2 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1391213-A1 | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents | Boehringer Ingelheim International GmbH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002098897-A2 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | disclosed |
| EP-1258255-A1 | Conjugates of an antibody to CD44 and a maytansinoid | Boehringer Ingelheim International GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| EP-1229934-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | Immunogen, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001024763-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | IMMUNOGEN, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| US-5208020-A | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0425235-A2 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1991-05-02 | — | — | EP | disclosed |
| EP-0425235-A2 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270361-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | SIGLEC7, CD2, CD22 | SMN1; SMN2 4708/4885ALDH1A1 2321/4885TSHR 1552/4885 |
| US-20250262217-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | FOLR1, FOLR2, DHFR | SMN1; SMN2 3057/4885ALDH1A1 754/4885TSHR 1668/4885 |
| US-20110256153-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | SIGLEC7, FUT7, CD2BP2 | SMN1; SMN2 4853/4885ALDH1A1 1331/4885TSHR 1940/4885 |
| US-20190167704-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | FOLR1, FOLR2, DHFR | SMN1; SMN2 3454/4885ALDH1A1 1302/4885TSHR 1430/4885 |
| US-20140099308-A1 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof | EGFR, ERBB2, ERBB4 | SMN1; SMN2 4858/4885ALDH1A1 3944/4885TSHR 1738/4885 |
| US-20060233811-A1 | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | CD47, ANXA5, CD44 | SMN1; SMN2 2821/4885ALDH1A1 1314/4885TSHR 4298/4885 |
| US-20170239367-A1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | FOLR1, FOLR2, DHFR | SMN1; SMN2 3057/4885ALDH1A1 754/4885TSHR 1668/4885 |
| US-20130156796-A1 | Method of Treatment of Tumors That Are Resistant to EGFR Therapies by EGFR Antibody Cytotoxic Agent Conjugate | EGFR, ALK, ERBB2 | SMN1; SMN2 4074/4885ALDH1A1 1426/4885TSHR 834/4885 |
| US-20120156217-A1 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof | EGFR, ERBB2, ERBB4 | SMN1; SMN2 4858/4885ALDH1A1 3944/4885TSHR 1738/4885 |
| US-11278628-B2 | Pharmaceutical formulations and methods of use thereof | GABRA5, GABRA6, GABRA3 | SMN1; SMN2 2995/4885ALDH1A1 1477/4885TSHR 1768/4885 |
| US-20220267371-A1 | METHODS FOR ANTIBODY DRUG CONJUGATION, PURIFICATION, AND FORMULATION | FCGR2A, FCGR1A, FCGR3B | SMN1; SMN2 3441/4885ALDH1A1 597/4885TSHR 863/4885 |
| US-20210155688-A1 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | FOLR1, FOLR2, DHFR | SMN1; SMN2 3057/4885ALDH1A1 754/4885TSHR 1668/4885 |
| US-20190183788-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | CD209, SIGLEC7, SIGLEC9 | SMN1; SMN2 3851/4885ALDH1A1 2307/4885TSHR 499/4885 |
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | SMN1; SMN2 2871/4885ALDH1A1 178/4885TSHR 2417/4885 |
| US-20160060345-A1 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof | EGFR, ERBB2, ERBB4 | SMN1; SMN2 4858/4885ALDH1A1 3944/4885TSHR 1738/4885 |
| US-20140023662-A1 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4832/4885ALDH1A1 4234/4885TSHR 1072/4885 |
| US-20210032327-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-20130295104-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | SIGLEC7, FUT7, CD2BP2 | SMN1; SMN2 4853/4885ALDH1A1 1331/4885TSHR 1940/4885 |
| US-20190270769-A1 | METHODS FOR ANTIBODY DRUG CONJUGATION, PURIFICATION, AND FORMULATION | FCGR2A, FCGR1A, FCGR3B | SMN1; SMN2 3441/4885ALDH1A1 597/4885TSHR 863/4885 |
| US-10301385-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-11395796-B2 | Anti-CD37 immunoconjugate and anti-CD20 antibody combinations | CD209, SIGLEC7, SIGLEC9 | SMN1; SMN2 3851/4885ALDH1A1 2307/4885TSHR 499/4885 |
| US-20160060339-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-11033564-B2 | Therapeutic combinations comprising anti-FOLR1 immunoconjugates | FOLR1, FOLR2, DHFR | SMN1; SMN2 3454/4885ALDH1A1 1302/4885TSHR 1430/4885 |
| US-20200222552-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | GABRA5, GABRA6, GABRA3 | SMN1; SMN2 2995/4885ALDH1A1 1477/4885TSHR 1768/4885 |
| US-20120009181-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-12559566-B2 | CD37-binding molecules immunoconjugates thereof | IGSF11, SIGLEC7, VSIG8 | SMN1; SMN2 4547/4885ALDH1A1 1676/4885TSHR 711/4885 |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | BCL9, BCL9L, BCL6B | SMN1; SMN2 3563/4885ALDH1A1 4572/4885TSHR 932/4885 |
| US-20040120949-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy | CD44, CD47, EPCAM | SMN1; SMN2 4221/4885ALDH1A1 239/4885TSHR 2498/4885 |
| US-11466095-B2 | CD37-binding molecules and immunoconjugates thereof | SIGLEC7, FUT7, CD2BP2 | SMN1; SMN2 4853/4885ALDH1A1 1331/4885TSHR 1940/4885 |
| US-20160108126-A1 | CD20 Antibodies and Uses Thereof | BCL9L, BCL9, BCL6B | SMN1; SMN2 4435/4885ALDH1A1 4245/4885TSHR 574/4885 |
| US-20160115238-A1 | CD20 Antibodies and Uses Thereof | BCL9L, BCL9, BCL3 | SMN1; SMN2 4468/4885ALDH1A1 4241/4885TSHR 557/4885 |
| US-20190218303-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | SIGLEC7, FUT7, CD2BP2 | SMN1; SMN2 4853/4885ALDH1A1 1331/4885TSHR 1940/4885 |
| US-20250345452-A1 | METHODS FOR THE TREATMENT OF PATIENTS WITH FOLATE RECEPTOR ALPHA-EXPRESSING CANCERS | FOLR1, FOLR2, TFRC | SMN1; SMN2 3414/4885ALDH1A1 2154/4885TSHR 148/4885 |
| US-20240368270-A1 | ANTI-FOLR1 IMMUNOCONJUGATE REGIMENS | FOLR1, FOLR2, DHFR | SMN1; SMN2 3175/4885ALDH1A1 677/4885TSHR 1660/4885 |
| US-20160326258-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | SIGLEC7, FUT7, CD2BP2 | SMN1; SMN2 4853/4885ALDH1A1 1331/4885TSHR 1940/4885 |
| US-20230190638-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | CD209, SIGLEC7, SIGLEC9 | SMN1; SMN2 3851/4885ALDH1A1 2307/4885TSHR 499/4885 |
| US-10603388-B2 | Methods for formulating antibody drug conjugate compositions | FCGRT, FCGR1A, FCGR3B | SMN1; SMN2 794/4885ALDH1A1 482/4885TSHR 2702/4885 |
| US-20240132585-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-20160083471-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-20160058884-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | FCGR1A, FCGR3B, FCGRT | SMN1; SMN2 737/4885ALDH1A1 521/4885TSHR 2607/4885 |
| US-20160096887-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-20150132323-A1 | Anti-FOLR1 Immunoconjugate Dosing Regimens | FOLR1, FOLR2, DHFR | SMN1; SMN2 3057/4885ALDH1A1 754/4885TSHR 1668/4885 |
| US-20170000900-A1 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | CD209, SIGLEC7, SIGLEC9 | SMN1; SMN2 3851/4885ALDH1A1 2307/4885TSHR 499/4885 |
| US-10556958-B2 | CD37-binding molecules and immunoconjugates thereof | SIGLEC7, CD2, CD22 | SMN1; SMN2 4708/4885ALDH1A1 2321/4885TSHR 1552/4885 |
| US-20130295119-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | FOLR1, FOLR2, DHFR | SMN1; SMN2 4513/4885ALDH1A1 632/4885TSHR 185/4885 |
| US-20200397806-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | FOLR1, FOLR2, DHFR | SMN1; SMN2 3454/4885ALDH1A1 1302/4885TSHR 1430/4885 |
| US-12239732-B2 | Anti-CD37 immunoconjugate and anti-CD20 antibody combinations | CD209, SIGLEC7, SIGLEC9 | SMN1; SMN2 3851/4885ALDH1A1 2307/4885TSHR 499/4885 |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | SMN1; SMN2 2871/4885ALDH1A1 178/4885TSHR 2417/4885 |
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | ITGB3, ITGB5, ITGB4 | SMN1; SMN2 2872/4885ALDH1A1 793/4885TSHR 2383/4885 |
| US-20110195022-A1 | CD20 ANTIBODIES AND USES THEREOF | BCL9, BCL9L, BCL6B | SMN1; SMN2 3563/4885ALDH1A1 4572/4885TSHR 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.